That's the end of regulation. Agniko Eagle Mines ringing the closing bell at the New York Stock Exchange.

JPMorgan Asset Management doing the honors at the NASDA.

It mixed end to a volatile session. We really basically failed to rally here as stocks did rally at the open through the session,

popped on hopes of averting a shutdown, and then drifted

lower here in the final moments into the close.

The major averages heading for big weekly losses after the Fed reset the narrative.

That is the scorecard on Wall Street.

But the action is just getting started.

Welcome to closing bell overtime.

I'm Morgan Brennan with John Ford.

Well, coming up this hour, two crucial reads on

retail and logistics during the holiday season. When we get earnings from Nike and FedEx, we're

going to have the numbers and expert analysis as soon as they cross. Plus, does an uncertain

Fed path and a less certain economy pour cold water in hopes of an M&A boom in 2025. We're going to ask the

managing partner of $90 billion private equity firm Advent for his take. And the FDA says it has

resolved the shortage of a key weight loss drug. And that's bad news for one of the year's

biggest health care winners. We'll explain why ahead. As we await earnings from FedEx and Nike,

though, let's break down today's market action with BD8 Capital Partners, CEO Barbara Duran,

and Morgan Stanley Global Chief Economist Seth Carpenter. It's great to have you both here.

Barbara, I'm going to start with you because we really failed to hang on to gains here,

X the Dow, which finished up, it looks like maybe 15 points, so fractionally higher today.

What does that tell us about the state of the market after the dramatic pullback we saw yesterday,

...